▲ Peaking
Business
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics faces severe downsizing and stock downgrades after the collapse of its cancer partnership with Lilly.
Fierce Biotech
8 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Definium's LSD-based anxiety, depression drug scores another trial win
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✗
Scientists boycott American Diabetes Association as fallout of June conference fracas escalates
Scientists and journal editors have launched a boycott of the American Diabetes Association following a June conference incident.
◼ Archived
Business
🔮 fades ✓
Novartis Says Closely Watched Cholesterol Study Failed to Meet Goal
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
AI brings savings to clinical trials: study
Recent studies and reports indicate that artificial intelligence is delivering substantial cost savings and efficiency to oncology clinical trials.
◼ Archived
Business
🔮 fades
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen defends its anti-tau drug following a stock decline triggered by a recent Alzheimer's treatment readout.
◼ Archived
Health
🔮 fades
BIO 2026: How a gut feeling transformed cancer treatment forever
Coverage from multiple industry outlets explores how engineered immune therapies and checkpoint inhibitors are transforming cancer treatment.